Compare Stocks: SLXN, BOLT, CELZ, and OSRH

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BOLT Bolt Biotherapeutics	$3.73 +1.4%	$3.87	$3.13 ▼ $7.20	$7.09M	1.09	15,397 shs	96,975 shs
CELZ Creative Medical Technology	$0.95 -8.6%	$1.01	$0.62 ▼ $6.25	$6.86M	2.04	798,030 shs	319,858 shs
OSRH OSR	$0.20 -8.7%	$0.35	$0.08 ▼ $0.91	$7.02M	0.49	6.44 million shs	512,995 shs
SLXN Silexion Therapeutics	$0.42 +20.9%	$1.44	$0.34 ▼ $77.70	$1.94M	-0.36	297,799 shs	118.42 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BOLT Bolt Biotherapeutics	-3.47%	-1.43%	-5.14%	-20.65%	-24.75%
CELZ Creative Medical Technology	-3.70%	-7.96%	-13.33%	-51.17%	-69.50%
OSRH OSR	+3.61%	-35.60%	-49.03%	-50.07%	-65.55%
SLXN Silexion Therapeutics	+1.33%	-0.48%	-76.70%	-88.69%	-99.31%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BOLT Bolt Biotherapeutics	$3.73 +1.4%	$3.87	$3.13 ▼ $7.20	$7.09M	1.09	15,397 shs	96,975 shs
CELZ Creative Medical Technology	$0.95 -8.6%	$1.01	$0.62 ▼ $6.25	$6.86M	2.04	798,030 shs	319,858 shs
OSRH OSR	$0.20 -8.7%	$0.35	$0.08 ▼ $0.91	$7.02M	0.49	6.44 million shs	512,995 shs
SLXN Silexion Therapeutics	$0.42 +20.9%	$1.44	$0.34 ▼ $77.70	$1.94M	-0.36	297,799 shs	118.42 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BOLT Bolt Biotherapeutics	-3.47%	-1.43%	-5.14%	-20.65%	-24.75%
CELZ Creative Medical Technology	-3.70%	-7.96%	-13.33%	-51.17%	-69.50%
OSRH OSR	+3.61%	-35.60%	-49.03%	-50.07%	-65.55%
SLXN Silexion Therapeutics	+1.33%	-0.48%	-76.70%	-88.69%	-99.31%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BOLT Bolt Biotherapeutics	2.25	Hold	$14.50	288.74% Upside
CELZ Creative Medical Technology	2.00	Hold	N/A	N/A
OSRH OSR	1.00	Sell	N/A	N/A
SLXN Silexion Therapeutics	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest SLXN, BOLT, CELZ, and OSRH Analyst Ratings

Date	Company	Brokerage	Action	Rating
8/27/2026	CELZ Creative Medical Technology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/20/2026	CELZ Creative Medical Technology	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/13/2026	CELZ Creative Medical Technology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/31/2026	CELZ Creative Medical Technology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/29/2026	SLXN Silexion Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/17/2026	BOLT Bolt Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/24/2026	OSRH OSR	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/15/2026	SLXN Silexion Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 9/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BOLT Bolt Biotherapeutics	$4.70M	1.53	N/A	N/A	$13.81 per share	0.27
CELZ Creative Medical Technology	$10K	626.18	N/A	N/A	$2.04 per share	0.47
OSRH OSR	$1.81M	3.88	N/A	N/A	$3.56 per share	0.06
SLXN Silexion Therapeutics	N/A	N/A	N/A	N/A	$8.33 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BOLT Bolt Biotherapeutics	-$33.38M	-$16.44	N/A	N/A	N/A	-611.47%	-126.23%	-54.70%	11/11/2026 (Estimated)
CELZ Creative Medical Technology	-$5.99M	-$2.07	N/A	N/A	N/A	N/A	-86.52%	-81.96%	11/6/2026 (Estimated)
OSRH OSR	-$27.06M	-$0.37	N/A	N/A	N/A	-593.15%	-8.36%	-6.24%	N/A
SLXN Silexion Therapeutics	-$11.91M	-$42.47	N/A	N/A	N/A	N/A	-563.11%	-201.73%	11/11/2026 (Estimated)

Latest SLXN, BOLT, CELZ, and OSRH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/15/2026	Q2 2026	SLXN Silexion Therapeutics	-$21.20	-$5.17	+$16.03	-$5.17	N/A	N/A
8/14/2026	Q2 2026	OSRH OSR	N/A	-$0.02	N/A	-$0.02	N/A	$0.32 million
8/11/2026	Q2 2026	BOLT Bolt Biotherapeutics	-$3.39	-$4.57	-$1.18	-$4.57	$0.50 million	$0.01 million
8/7/2026	Q2 2026	CELZ Creative Medical Technology	-$0.39	-$0.41	-$0.02	-$0.41	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BOLT Bolt Biotherapeutics	$0.36	9.65%	N/A	N/A	N/A
CELZ Creative Medical Technology	N/A	N/A	N/A	N/A	N/A
OSRH OSR	N/A	N/A	N/A	N/A	N/A
SLXN Silexion Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BOLT Bolt Biotherapeutics	1.47	2.61	2.61
CELZ Creative Medical Technology	N/A	12.90	12.90
OSRH OSR	N/A	0.18	0.14
SLXN Silexion Therapeutics	N/A	0.94	0.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BOLT Bolt Biotherapeutics	86.70%
CELZ Creative Medical Technology	1.42%
OSRH OSR	55.30%
SLXN Silexion Therapeutics	10.95%

Insider Ownership

Company	Insider Ownership
BOLT Bolt Biotherapeutics	9.40%
CELZ Creative Medical Technology	1.00%
OSRH OSR	36.90%
SLXN Silexion Therapeutics	0.77%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BOLT Bolt Biotherapeutics	90	1.93 million	1.75 million	Not Optionable
CELZ Creative Medical Technology	5	6.59 million	6.53 million	Not Optionable
OSRH OSR	N/A	35.12 million	22.16 million	N/A
SLXN Silexion Therapeutics	N/A	5.56 million	5.52 million	N/A

SLXN, BOLT, CELZ, and OSRH Headlines

Recent News About These Companies

5 Biotech Stocks In Spotlight: Tenon Medical, AEON Biopharma, Silexion, Orchestra BioMed & Indaptus

4 hours ago | rttnews.com

Silexion Therapeutics to Participate in September 2026 Industry and Investor Conferences

September 9 at 9:00 AM | globenewswire.com

Silexion Posts Wider Q2 Loss On Higher SIL-204 Development Costs

September 4, 2026 | rttnews.com

After Moderna’s $44B Oncology Win, Silexion’s Pancreatic Cancer Treatment is Worth Exploring (NASDAQ: SLXN)

August 25, 2026 | markets.businessinsider.com

Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

August 14, 2026 | globenewswire.com

Silexion Therapeutics Prices $2.5 Million Securities Offering; Shares Down Pre-Bell

August 12, 2026 | finance.yahoo.com

Silexion Therapeutics Prices $2.5 Million Public Offering of Ordinary Shares and Warrants

August 11, 2026 | quiverquant.comQ

Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering

August 11, 2026 | globenewswire.com

Immunotherapy's Biggest Blind Spot Is a $7 Billion Market. Silexion May Have a Way In (NASDAQ: SLXN)

August 10, 2026 | markets.businessinsider.com

Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers

August 4, 2026 | finance.yahoo.com

Silexion Therapeutics Reports Preclinical Data Showing SIL204 Immune-Sensitizing Effects in KRAS-Mutant Cancer Cells

August 4, 2026 | quiverquant.comQ

Silexion Therapeutics Announces Board Member Resignation

July 31, 2026 | tipranks.com

Silexion Therapeutics Initiates Phase 2/3 Trial for Pancreatic Cancer Drug Candidate

July 30, 2026 | finance.yahoo.com

Silexion Activates First Site in Phase 2/3 Trial Targeting KRAS-Driven Pancreatic Cancer (NASDAQ: SLXN)

July 29, 2026 | markets.businessinsider.com

Silexion Therapeutics initiates phase 2/3 trial of SIL204 in pancreatic cancer

July 29, 2026 | msn.com

Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center

July 29, 2026 | globenewswire.com

Silexion Therapeutics

July 21, 2026 | fool.com

Silexion Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:SLXN

July 1, 2026 | benzinga.com

Silexion Therapeutics Receives BfArM Approval to Initiate Phase 2/3 SIL204 Trial in Germany

June 23, 2026 | quiverquant.comQ

Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

June 23, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

SLXN, BOLT, CELZ, and OSRH Company Descriptions

Bolt Biotherapeutics NASDAQ:BOLT

$3.73 +0.05 (+1.36%)

Closing price 03:57 PM Eastern

Extended Trading

$3.58 -0.15 (-4.05%)

As of 07:55 PM Eastern

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

Creative Medical Technology NASDAQ:CELZ

$0.95 -0.09 (-8.63%)

Closing price 04:00 PM Eastern

Extended Trading

$0.95 0.00 (-0.02%)

As of 07:58 PM Eastern

Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

OSR NASDAQ:OSRH

$0.20 -0.02 (-8.68%)

As of 03:57 PM Eastern

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D "platform technologies" versus "assets only" companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.

Silexion Therapeutics NASDAQ:SLXN

$0.42 +0.07 (+20.89%)

Closing price 04:00 PM Eastern

Extended Trading

$0.42 -0.01 (-1.78%)

As of 07:59 PM Eastern

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SLXN, BOLT, CELZ, and OSRH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SLXN, BOLT, CELZ, and OSRH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SLXN, BOLT, CELZ, and OSRH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SLXN, BOLT, CELZ, and OSRH Company Descriptions

Bolt Biotherapeutics NASDAQ:BOLT

Creative Medical Technology NASDAQ:CELZ

OSR NASDAQ:OSRH

Silexion Therapeutics NASDAQ:SLXN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SLXN, BOLT, CELZ, and OSRH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SLXN, BOLT, CELZ, and OSRH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SLXN, BOLT, CELZ, and OSRH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SLXN, BOLT, CELZ, and OSRH Company Descriptions

Bolt Biotherapeutics NASDAQ:BOLT

Creative Medical Technology NASDAQ:CELZ

OSR NASDAQ:OSRH

Silexion Therapeutics NASDAQ:SLXN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools